A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs HTERT DNA vaccine Invectys (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Invectys
- 09 Sep 2019 According to a Personalis media release, the company announced that it has entered into a research agreement with Invectys. Personalis will provide comprehensive tumor immunogenomics capabilities to facilitate biomarker discovery in chronic lymphocytic leukemia (CLL) patients enrolled in this study.
- 12 Jul 2019 Planned number of patients changed from 84 to 90.
- 31 Aug 2018 Biomarkers information updated